Unknown

Dataset Information

0

Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice.


ABSTRACT: TOR (Target of Rapamycin) pathway accelerates cellular and organismal aging. Similar to rapamycin, p53 can inhibit the mTOR pathway in some mammalian cells. Mice lacking one copy of p53 (p53+/- mice) have an increased cancer incidence and a shorter lifespan. We hypothesize that rapamycin can delay cancer in heterozygous p53+/- mice. Here we show that rapamycin (given in a drinking water) extended the mean lifespan of p53+/- mice by 10% and when treatment started early in life (at the age less than 5 months) by 28%. In addition, rapamycin decreased the incidence of spontaneous tumors. This observation may have applications in management of Li-Fraumeni syndrome patients characterized by heterozygous mutations in the p53 gene.

SUBMITTER: Komarova EA 

PROVIDER: S-EPMC3517941 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9828006 | biostudies-literature
| S-EPMC2786175 | biostudies-literature
| S-EPMC6687560 | biostudies-literature
| S-EPMC3726163 | biostudies-other
| S-EPMC5596098 | biostudies-literature
| S-EPMC5886265 | biostudies-literature
| S-SCDT-EMBOR-2022-55299V1 | biostudies-other
| S-EPMC9442325 | biostudies-literature
| S-EPMC3753544 | biostudies-other
| S-EPMC6516426 | biostudies-literature